The underperforming biotech featured in today’s article may be well positioned to become an outperformer. How? As the author explains, the company “may soon be able to squeeze more juice from its crown jewel” by expanding its non-steroidal anti-inflammatory medication, currently approved for the treatment of a rare type of blood cancer, into dermatology. For more, CLICK HERE.
Expanding Its “Crown Jewel” Medication Into Dermatology Could Take This Biotech From Underperformer To Outperformer
- by RobH